Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Vaccines

Therapeutic area intelligence for Vaccines with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 2

Companies

MenACWY-CRM →

Assets

Recent signals(7)

ClinicalAugust 5, 2026

Phase III Trial Shows Safe Co-Administration of PCV15 and DTaP in Infants

A phase III trial demonstrated that co-administration of PCV15 and DTaP in infants is safe and immunogenic, with no significant adverse interactions.

July 15, 2026

Study on Shingrix Vaccine Response in HIV Patients and Healthy Controls

A clinical trial is investigating the safety and immunogenicity of the Shingrix vaccine in individuals with HIV and healthy controls.

StrategyJuly 12, 2026

Phase II Trial Shows Comparable Immunogenicity of GSK's Investigational MMRV Vaccine

GSK's investigational MMRV vaccine demonstrated comparable immunogenicity and safety to the licensed MMRV vaccine in Phase II trial.

ClinicalJuly 4, 2026

Study shows no autoantibody induction post-BNT162b2 boost in CoronaVac-primed individuals

No significant changes in autoantibody profiles were observed 26 weeks after BNT162b2 boosting in individuals primed with CoronaVac.

StrategyJuly 4, 2026

Phase III Trial Shows Non-Inferior Immunogenicity of PCV-Free Rotavirus Vaccine in Infants

The Phase III trial demonstrated that the PCV-free Rotarix vaccine achieved non-inferior seroconversion rates compared to the original Rotarix.

ClinicalJune 28, 2026

Hexavalent DTaP-IPV-HB-Hib Vaccine Shows Immunogenicity in Preterm Infants

A phase IV trial in Spain found that a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine is immunogenic and well tolerated in preterm infants.

ClinicalJune 11, 2026

4CMenB and MenACWY-CRM Vaccines Co-Administered Safely in Adolescents

A phase 3b study demonstrated that co-administration of 4CMenB and MenACWY-CRM in adolescents is safe and immunogenic.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.